SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 3.1% Passive Stake in Neurogene Inc.
Beneficial Ownership Statement
FMR LLC and its affiliates, along with Abigail P. Johnson, have filed an amended Schedule 13G disclosing a passive beneficial ownership of 3.1% of Neurogene Inc.'s common stock as of March 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson reported beneficial ownership of 462,879 shares of Neurogene Inc. common stock.
- This represents 3.1% of the total outstanding common stock of Neurogene Inc.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment.
- FMR LLC holds sole voting power over 462,696 shares and sole dispositive power over 462,879 shares.
- Abigail P. Johnson, as a predominant owner and CEO of FMR LLC, is also reported as beneficially owning 462,879 shares with sole dispositive power.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Neurogene Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing beneficial ownership. It contains factual information about shareholdings and does not provide positive or negative commentary on the issuer's performance or outlook, thus maintaining a neutral sentiment.
Positives
- A significant institutional investor, FMR LLC, maintains a 3.1% stake in Neurogene Inc., indicating continued interest.
- The investment is stated to be for ordinary course of business, not for control, suggesting a stable, passive holding.
Future Outlook
NA
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."
Industry Context
This Schedule 13G filing reflects a passive investment by a major asset management firm, FMR LLC, in Neurogene Inc., a biotechnology company. Such filings are routine disclosures for institutional investors holding significant, non-controlling stakes, and do not typically provide insights into the issuer's industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency on a significant institutional holding, which can influence market perception.
- Employees, Customers, Suppliers, Creditors: No direct impact from this ownership disclosure.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/10/2023 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000003) was incorporated by reference. |
| 01/26/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 01/31/2023 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000038) for Abigail P. Johnson was incorporated by reference. |
| 03/31/2025 | Date of event which requires filing of this statement (reporting period end date). |
| 05/09/2025 | Date of signing and filing of this Schedule 13G Amendment No. 1. |
Keywords
Neurogene Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investment, passive investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.